James M. Oliphant
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Agricultural Research Service (2008); United States Food and Drug Administration (2024–2025); United States Department of Agriculture (2008); National Clonal Germplasm Repository (2008); Ministère de l'Agriculture, des Pêcheries et de l'Alimentation (1974); Food and Drug Administration (2025)
Unknown Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
James M. Oliphant's research focuses on identifying biomarkers for disease severity, particularly in the context of COVID-19. He has published work utilizing untargeted metabolomics and lipidomics to discover potential indicators of COVID-19 severity in patient plasma. His research also extends to evaluating risk factors for complications in surgical procedures, such as total hip arthroplasty, by examining factors like BMI and fat distribution.
Further research interests include the development of climate scenarios for maintaining clonal germplasm of various berry species and their wild relatives, alongside confirming cultivar identity through genetic fingerprinting. Oliphant also investigates challenges and solutions in measuring biomarkers for drug-induced liver injury using in vitro platforms and validating the use of New Approach Methodologies (NAMs) for toxicity screening and drug development, specifically in cardiac contexts. His scholarly output includes 9 publications with a citation count of 77 and an h-index of 4.
Metrics
- h-index: 4
- Publications: 9
- Citations: 78
Selected Publications
-
Evaluation of BMI and fat distribution as potential risk factors for infection and wound healing complications in total hip arthroplasty (2026)
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers (2024)
Collaboration Network
Top Collaborators
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
Similar Researchers
Based on overlapping research topics